The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas
Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach. Modern local therapies have led to a paradigm shift, making long-term disease-free survival possible for selected groups of metas...
| Published in: | Nowotwory |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2023-02-01
|
| Subjects: | |
| Online Access: | https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/view/91895 |
| Summary: | Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach. Modern local therapies have led to a paradigm shift, making long-term disease-free survival possible for selected groups of metastatic sarcoma patients. Oligometastatic and oligoprogressive disease constitute such indications. Although the administration of stereotactic radiation therapy (SBRT) for sarcoma metastases has been continuously rising over the past years, the evidence for such treatment is relatively scarce, lacking in larger prospective randomized clinical trials, and there is no consensus regarding strict indications, patient selection, and the time order of multimodal treatment. In this article, we discuss available clinical data regarding the efficacy and safety of SBRT in oligometastatic and oligoprogressive sarcoma, highlighting its indications in specific organ sites, as well as the possible limitations of this treatment modality. |
|---|---|
| ISSN: | 0029-540X 2300-2115 |